CAR-T cell therapy advancements
On April 17, 2026, a phase 1 trial of intraventricular HER2-directed CAR T-cells for HER2-positive breast cancer with CNS metastases demonstrated a manageable safety profile and stable disease rates in heavily pretreated patients. As of May 10, 2026, researchers are developing new CAR-T cell therapy strategies for solid tumors, including combinations with mRNA vaccines or oncolytic viruses, and engineering 'armored' CARs to improve efficacy. Preclinical models have shown significant tumor reduction and extended survival with 'armored' CAR-T cells blocking VEGF, and a novel CAR-T therapy targeting HER2-expressing tumors achieved complete tumor disappearance in xenograft models. The C406 CAR-T therapy for HER2-positive breast cancer demonstrated a 75% disease control rate in a phase I study, while a universal CAR-T cell immunotherapy achieved full remission in most patients with aggressive blood cancers in a Phase 1/2 clinical trial. The University of Chicago has also developed GA1CAR, a modular "plug-and-play" CAR-T system, and reported the first successful in vivo engineering of CAR T cells at a therapeutic level for both hematologic and solid cancers.
Timeline
Want updates on this thread?
Track this storyTimeline of developments
May 2026 — 1 developments
Researchers are developing new CAR-T cell therapy strategies for solid tumors, including combination…
Researchers are developing new CAR-T cell therapy strategies for solid tumors, including combinations with mRNA vaccines or oncolytic viruses, and engineering 'armored' CARs to improve efficacy. Genetic modifications, such as deleting the CDKN1B gene, are also being studied to enhance CAR-T cell proliferation and anti-tumor activity.
April 2026 — 10 developments
The development of CAR-T cell therapies for various cancers and autoimmune diseases is anticipated to grow significantly over the next 5-10 years.
The development of CAR-T cell therapies for various cancers and autoimmune diseases is anticipated to grow significantly over the next 5-10 years. Research is focusing on refining CAR constructs for improved specificity and reduced toxicity, developing better management protocols for side effects, exploring allogeneic CAR-T platforms for broader access, and enhancing T-cell trafficking for solid tumors.
A phase 1 trial of intraventricular HER2-directed CAR T-cells for HER2-positive breast cancer with C…
A phase 1 trial of intraventricular HER2-directed CAR T-cells for HER2-positive breast cancer with CNS metastases has shown a manageable safety profile and stable disease rates in heavily pretreated patients. Additionally, a new generation of base-edited CAR T-cells (BE-CAR7) shows promise in treating aggressive T-cell leukemia, contributing to the 'CAR-T 2.0 era' focused on rapid manufacturing and reduced toxicity.
The C406 CAR-T therapy targeting HER2-positive breast cancer demonstrated a 75% disease control rate in a phase I study, with manageable adverse events.
The C406 CAR-T therapy targeting HER2-positive breast cancer demonstrated a 75% disease control rate in a phase I study, with manageable adverse events. Ongoing research continues to focus on developing next-generation CAR-T cells, including GA1CAR, for improved persistence, reduced toxicity, and better tumor microenvironment penetration.
A novel CAR-T therapy targeting HER2-expressing tumors, engineered to secrete a bispecific antibody …
A novel CAR-T therapy targeting HER2-expressing tumors, engineered to secrete a bispecific antibody against HER2 and p95HER2, has demonstrated significant tumor reduction in preclinical models. A Phase 1 clinical trial for this therapy is currently in development.
New research explores next-generation CAR-T cell therapies targeting HER2 for solid tumors, with one…
New research explores next-generation CAR-T cell therapies targeting HER2 for solid tumors, with one novel CAR-T achieving safe, complete, and durable responses in preclinical models, leading to complete tumor disappearance in xenograft models. Concurrently, new CAR-T manufacturing methods are being developed to improve efficacy and reduce costs, including a multi-cytokine scaffold for longer-lived immune cells and a controlled immune response CAR-T for safer blood cancer treatment.
A novel CAR T-cell therapy targeting the HER2 antigen has shown efficacy and safety in preclinical m…
A novel CAR T-cell therapy targeting the HER2 antigen has shown efficacy and safety in preclinical models of HER2-positive solid tumors, including breast and ovarian cancers, and is being explored for integration with radiation therapy. In a Phase I clinical trial for advanced sarcoma, 50% of treated patients experienced clinical benefit, with one patient achieving a durable, cancer-free response lasting over five years.
UCLA scientists have developed 'armored' CAR-T cells engineered to overcome the immunosuppressive tumor microenvironment by blocking VEGF.
UCLA scientists have developed 'armored' CAR-T cells engineered to overcome the immunosuppressive tumor microenvironment by blocking VEGF. These modified cells demonstrated a significant reduction in tumor growth and extended survival in preclinical models of glioblastoma and ovarian cancer.
A universal CAR-T cell immunotherapy has shown promising results in a Phase 1/2 clinical trial for aggressive blood cancers, with most patients achieving full remission.
A universal CAR-T cell immunotherapy has shown promising results in a Phase 1/2 clinical trial for aggressive blood cancers, with most patients achieving full remission. Additionally, an "off-the-shelf" CAR-T therapy demonstrated significant reductions in molecular residual disease (MRD) and achieved MRD clearance in patients with large B-cell lymphoma. Researchers at the University of Chicago developed GA1CAR, a modular "plug-and-play" CAR-T system offering enhanced safety and adaptability.
Researchers have reported the first successful in vivo engineering of CAR T cells at a therapeutic level for both hematologic and solid cancers.
Researchers have reported the first successful in vivo engineering of CAR T cells at a therapeutic level for both hematologic and solid cancers. This advancement, developed by the University of Chicago, aims to make treatments more efficient and precise by engineering T cells within the patient's body. This approach could potentially overcome challenges associated with ex vivo manufacturing.
C406 CAR-T therapy has demonstrated significant potential in preclinical studies for treating various cancers.
C406 CAR-T therapy has demonstrated significant potential in preclinical studies for treating various cancers. This therapy is designed to overcome common challenges in CAR-T treatment, such as tumor resistance and T-cell exhaustion. Further research is ongoing to optimize its efficacy and safety profile for potential clinical translation.
March 2026 — 1 developments
A novel CAR T-cell therapy targeting the HER2 antigen has demonstrated safety and clinical benefit in patients with advanced sarcoma during a Phase 1 clinical trial.
A novel CAR T-cell therapy targeting the HER2 antigen has demonstrated safety and clinical benefit in patients with advanced sarcoma during a Phase 1 clinical trial. Researchers at Baylor College of Medicine and Texas Children's Hospital are leading this study. Another related study reported on a second-generation CAR T-cell therapy targeting p95HER2, which showed safety and complete, durable responses in preclinical models.
January 2026 — 1 developments
New CRISPR-based screening methods are presented, identifying gene targets that could further enhanc…
New CRISPR-based screening methods are presented, identifying gene targets that could further enhance CAR T-cell proliferation and anti-tumor activity, indicating ongoing efforts to refine CAR-T technologies.
December 2025 — 1 developments
A clinical trial for a different CAR-T therapy (GCAR1), an autologous CAR-T for solid tumors, is fir…
A clinical trial for a different CAR-T therapy (GCAR1), an autologous CAR-T for solid tumors, is first posted, with a study start date of January 31, 2026, indicating ongoing clinical translation efforts in CAR-T for solid tumors.
August 2025 — 1 developments
A review article discusses the broader landscape of UCAR-T cell engineering and clinical strategies,…
A review article discusses the broader landscape of UCAR-T cell engineering and clinical strategies, noting progress in hematological malignancies but persistent challenges in solid tumors, underscoring the importance of GA1CAR's advancements.
May 2025 — 1 developments
An international Phase 1/2 clinical trial for a new universal CAR-T cell therapy for aggressive T ce…
An international Phase 1/2 clinical trial for a new universal CAR-T cell therapy for aggressive T cell cancers showed promising outcomes, including high response and remission rates with manageable toxicity.
November 2024 — 1 developments
A universal CAR-T therapy targeting aggressive T-cell cancers has received FDA Breakthrough Status, showing a high overall response rate in a clinical trial.
A universal CAR-T therapy targeting aggressive T-cell cancers has received FDA Breakthrough Status, showing a high overall response rate in a clinical trial. Additionally, a new 'armored' CAR-T cell therapy, enhanced with IL-18, has demonstrated significant responses in lymphoma patients resistant to existing CAR-T treatments.
October 2021 — 1 developments
The concept of Universal CAR-T (UCAR-T) cell therapy gains significant attention as a strategy to overcome the manufacturing and cost limitations of autologous CAR-T.
The concept of Universal CAR-T (UCAR-T) cell therapy gains significant attention as a strategy to overcome the manufacturing and cost limitations of autologous CAR-T.
August 2017 — 1 developments
The U.S. FDA grants approval to Kymriah (tisagenlecleucel), the first CAR T-cell therapy, for acute …
The U.S. FDA grants approval to Kymriah (tisagenlecleucel), the first CAR T-cell therapy, for acute lymphoblastic leukemia (ALL), marking a major regulatory and clinical breakthrough.
January 2010 — 1 developments
The first successful clinical application of CAR T-cells in a patient with chronic lymphocytic leuke…
The first successful clinical application of CAR T-cells in a patient with chronic lymphocytic leukemia (CLL) at the University of Pennsylvania achieves complete remission, demonstrating the therapy's potential.
January 2003 — 1 developments
Dr. Michel Sadelain's group introduces CD19-targeting CAR T cells, a pivotal development that sets t…
Dr. Michel Sadelain's group introduces CD19-targeting CAR T cells, a pivotal development that sets the stage for effective CAR T-cell therapies in hematological malignancies.
January 1993 — 1 developments
Landmark studies demonstrate the ability to genetically engineer human T cells to recognize and kill…
Landmark studies demonstrate the ability to genetically engineer human T cells to recognize and kill cancer, and the first-generation CARs are created, though initial in vivo efficacy is limited.
January 1987 — 1 developments
The foundational concept of chimeric antigen receptors (CARs) is first proposed by researchers, laying the theoretical groundwork for CAR T-cell therapy.
The foundational concept of chimeric antigen receptors (CARs) is first proposed by researchers, laying the theoretical groundwork for CAR T-cell therapy.